The high cost of developing Enterobacter spp. generation III cephalosporins

The results of a study by scientists from the United States and Israel justify associating an increase in the number of deaths and hospitalizations, as well as an increase in the cost of treatment in a hospital environment with the appearance of Enterobacter spp in microorganisms. resistance to third generation cephalosporins.

The scientists analyzed the results and the cost of treatment in a cohort of patients in which the isolated Enterobacter strains were initially sensitive to cephalosporins. Next, the group of patients from whom resistant enterobacteria were subsequently isolated (n = 46) was compared to those in which no infection caused by resistant strains was detected (n = 113).

In the first group, mortality was higher than in the second (26% vs 13% of patients). After calculations taking into account the concomitant pathologies, the severity of the disease and other factors, it was found that the development of resistance to cephalosporins in Enterobacter spp. increases the risk of death by 5 times. In patients infected with resistant strains, the time spent in hospital increased by 1.5 times compared to those who did not have such an infection (30 vs 19 days). In addition, treatment costs were also 1.5 times higher in the first group of patients ($ 79,323 vs $ 40,406 per patient).